文献速递肝病

通用达拉他韦联合索磷布韦,联合或不联合利巴韦林,治疗慢性丙型肝炎:埃及18 378例患者的真实世界结果

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
PubMed 文献 · Aliment Pharmacol Ther · 2017-11-29

埃及国家丙型肝炎治疗项目纳入18 378例基因4型慢性丙型肝炎患者,接受通用达拉他韦60 mg联合索磷布韦400 mg,联合或不联合利巴韦林治疗12周。总体SVR12为95.1%,联合利巴韦林组为94.7%,不联合利巴韦林组为95.4%(P=0.32)。仅1.5%的患者提前终止治疗。

要点

  • 基因4型慢性丙型肝炎患者接受通用索磷布韦联合达拉他韦治疗12周,总体SVR12达95.1%。
  • 联合利巴韦林组SVR12为94.7%,不联合利巴韦林组为95.4%,两组间无显著差异(P=0.32)。
  • 仅1.5%的患者提前终止治疗,最常见原因为患者退出(n=76)和妊娠(n=5)。

核心结论

  • 通用索磷布韦联合达拉他韦在基因4型慢性丙型肝炎患者中证实安全,且在不同纤维化阶段患者中均与高SVR12率相关。

研究设计与样本

  • 埃及国家丙型肝炎治疗项目的真实世界数据,纳入18 378例基因4型慢性丙型肝炎患者,接受通用达拉他韦60 mg联合索磷布韦400 mg,联合或不联合利巴韦林治疗12周。
  • 初治无肝硬化患者不联合利巴韦林治疗,肝硬化或经治患者(干扰素经治或索磷布韦经治)接受利巴韦林治疗。
  • 评估疗效与安全性,并探索与治疗后第12周持续病毒学应答(SVR12)相关的基线因素。

主要发现

  • 项目启动后前2个月内,18 378例基因4型慢性丙型肝炎患者开始接受索磷布韦联合达拉他韦,联合或不联合利巴韦林治疗。
  • 总体95.1%达到SVR12;不联合利巴韦林组为95.4%,联合利巴韦林组为94.7%(P=0.32)。
  • 仅1.5%的患者提前终止治疗,最常见导致终止的事件为患者退出(n=76)和妊娠(n=5)。
  • 该组患者中发生5例死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of chronic hepatitis C using combination of sofosbuvir (SOF) and daclatasvir (DCV) was used in several clinical trials and multicentre studies, which were somewhat limited to genotypes 1-3. The national program in Egypt is using SOF-DCV combination for large scale treatment. AIM: To assess the efficacy and safety of combined SOF-DCV in treating patients with HCV-G4 in a real-world setting. METHODS: Data and outcome of chronic HCV patients who were treated for 12 weeks with generic medications: DCV 60 mg plus SOF 400 mg ± ribavirin (RBV) within the national hepatitis C treatment program in Egypt are presented. Treatment-naïve patients without cirrhosis were treated without RBV, and those who had cirrhosis or were treatment-experienced (interferon experienced or SOF experienced) received RBV. Efficacy and safety were assessed, and baseline factors associated with sustained virological response at post-treatment week 12 (SVR12) were explored. RESULTS: During the first 2 months of the programme, 18 378 patients with HCV-G4 started treatment with SOF-DCV with or without RBV. Overall, 95.1% achieved SVR12 (95.4% among patients treated without RBV and 94.7% for patients treated with RBV, P = .32). Treatment was prematurely discontinued in only 1.5% of patients. The most common events leading to discontinuation were patient withdrawal (n = 76) and pregnancy (n = 5). Five deaths occurred within this group. CONCLUSIONS: Real-world experience of generic SOF-DCV in patients with chronic HCV-G4 proved to be safe and associated with a high SVR12 rate, in patients with different stages of fibrosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2017. PMID: 29193226. doi:10.1111/apt.14428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。